Melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24) is a novel candidate of tumor suppressor that can selectively induce apoptosis experimentally in a spectrum of human cancer cells including leukemia cells. However, a recent study suggests that mda-7/IL-24 promotes the survival of chronic lymphocytic leukemia B-cells. In this study, we showed that mda-7/IL-24 was constitutively expressed in leukemia cell lines and primary acute myeloid leukemia samples. Using a conditionally replicating adenovirus expressing mda-7/IL-24 (ZD55-IL-24), we showed that enforced expression of mda-7/IL-24 in leukemia cells induced autophagy, which was triggered by the upregulation of Beclin-1. Immunofluorescence and coimmunoprecipitation studies suggested that mda-7/IL-24 protein interacts with Beclin-1. Class III PI3K/Beclin-1 complex was shown involved in the mda-7/IL-24-induced autophagy. Moreover, autophagy inhibition by phosphatidylinositol 3-kinase inhibitor, wortmannin, resulted in a reduced Beclin-1 expression and autophagosome formation associated with significantly enhanced cell death. Importantly, the combination of ZD55-IL-24 with wortmannin elicited a strongly enhanced antileukemia efficacy in established leukemia xenografts. These results suggest that mda-7/IL-24-induced autophagy in leukemia cells may provide survival advantage and mda-7/IL-24 combined with agents that disrupt autophagy is a promising new strategy for the treatment of leukemia.
Introduction
Melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24), a novel member of the IL-10 gene family, was first identified in human melanoma cell lines induced to differentiate by interferon-b and mezerein. 1 Expression of mda-7/IL-24 mRNA has been observed in normal melanocytes and early stages of melanoma, but not in cell lines derived from advanced tumors. 2 An earlier clinical study has documented a clinical significance of mda-7/IL-24 expression in which mda-7/IL-24 expression is downregulated with progression of melanoma. 3 Additionally, high expression of mda-7/IL-24 in tumor cells has been reported to be a significant factor to predict a favorable prognosis in the patients with lung adenocarcinoma. 4 Furthermore, adenovirus or nanoparticlemediated overexpression of mda-7/IL-24 has been shown to selectively inhibit cell growth and induce apoptosis in various human tumor cell lines, including those derived from the skin, prostate, breast, gastrointestinal tract, and lung without exerting deleterious effects in normal human cells. [5] [6] [7] [8] The first reported in vivo experiment of mda-7/ IL-24 showed that ectopic expression of mda-7/IL-24 delivered by a recombinant adenovirus inhibited human breast tumor growth in nude mice. 9 The antitumor effect of mda-7/Il-24 was also shown in different murine cancer models [10] [11] [12] and in phase I clinical trials. 13, 14 Collectively, the results suggest that the mda-7/IL-24 gene is a novel tumor suppressor gene and can be a novel target of cancer therapy.
Autophagy is a highly conserved cellular process in which the cell sequesters cytoplasmic contents in a double-membrane vesicle and delivers them to the lysosome for degradation. As cancer cells often display defective autophagic capacities, 15 autophagy is thought to be a tumor suppressor mechanism. The cytotoxicity of a number of antineoplastic therapies and some cytokines has been shown to be mediated via their induction of autophagy. [16] [17] [18] For example, in glioma and leukemia cells, arsenic trioxide-induced autophagy has a central function in the elimination of tumor cells by triggering a nonapoptotic cell death program. 19, 20 Contradictory to its cancer suppressive-function, autophagy has now been shown to represent a mechanism of resistance to therapymediated tumor cell death. 21, 22 Indeed, inhibition of autophagy with siRNAs targeted against autophagyrelated genes (ATG) usually accelerates cell death, suggesting that autophagy activation represents a cellular attempt to cope with stress induced by cytotoxic agents. 23 In this study, we investigated mda-7/IL-24 expression in leukemia cells and the effects of overexpressed mda-7/ IL-24 on autophagy in human leukemia cell lines. We found that overexpression of mda-7/IL-24-induced autophagy, which was triggered by the upregulation of Beclin-1, and that the inhibition of autophagy caused an enhanced cell death in vitro, suggesting that the autophagy may protect leukemia cells from the mda-7/IL-24-induced apoptosis. To determine whether the beneficial effects of disrupting autophagy could be obtained in vivo, we treated leukemia xenografts in severe combined immunodeficient (SCID) mouse with ZD55-IL-24, a conditionally replicating adenovirus (CRAd) carrying mda-7/IL-24, combined with a phosphatidylinositol 3-kinase (PI3K) inhibitor, which inhibited mda-7/IL-24-induced autophagy. This treatment resulted in a significant suppression of tumor growth, suggesting t hat mda-7/IL-24 combined with agents that disrupt autophagy is a promising new strategy for treatment of leukemia.
Materials and methods

Cell lines and patient samples
Human acute T lymphoblastic leukemia cell line Molt-4, B-lymphoblastic leukemia cell line Mutz-1, lymphoma cell line L428, monocyte leukemia cell lines THP and U937, acute myeloid leukemia (AML) cell line Kasumi and NB4, and chronic myeloid leukemia cell line K562 cells were maintained at 37 1C in 5% CO 2 in RPMI1640 medium, supplemented with 10% fetal bovine serum (Invitrogen, CA) as reported earlier. 24 Bone marrow samples from patient with AML and peripheral blood samples from five healthy donors were processed after they had given informed consent to the Institute of Hematology, Zhejiang University. This study obtained approval of the local ethics committee. Mononuclear cells (MNCs) were obtained from heparinized samples by centrifugation through a Ficoll-Hypaque density gradient (Shanghai biochemical reagent factory, Shanghai, China), and prepared for western blotting analysis.
Recombinant adenoviruses and MTT assay
The recombinant adenoviruses used in this study were described earlier, 25, 26 which included oncolytic adenovirus ZD55, ZD55 carrying mda-7/IL-24 (ZD55-IL-24), and nonreplicating adenovector carrying mda-7/IL-24 (Ad-IL-24). The expansion, purification, titration and quality analyses of those viruses were performed at the vector core facility of our institute. Leukemia cell lines were treated with recombinant adenoviruses alone or combined with wortmannin (Sigma, MS). The cell viability was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) assay as described earlier. 27 Stable transfection of GFP-LC3 in leukemia cells and visualization of MDC-labeled vacuoles pGFP-LC3 plasmids 28 kindly provided by Prof. Tamotsu Yoshimori (Research institute for microbial disease, Okazaki, Japan) were transfected into leukemia cell lines using electroproration system (Bio Rad, CA) at five pulses of 350 V, 5 ms, with 2.5 mg plasmid per 10 6 cells in 4 mm gap cuvettes. Forty-eight hours after transfection, the cells were selected with 1 mg ml -1 of G418 for 2 weeks. For the visualization of MDC-labeled vacuoles, cells were labeled with 0.1 mM monodansylcadaverine (MDC; Sigma) in PBS at 37 1C for 60 min. Cells were treated with or without ZD55-IL-24, fixed with 3% paraformaldehyde, and examined under a fluorescent inverted microscope with a digital camera. Only cells with at least five spots were counted as positive. Results are from at least three independent experiments.
Detection and quantification of acidic vesicular organelles with acridine orange Autophagy is the process of sequestrating cytoplasmic proteins into the lytic component and is characterized by the formation of acidic vesicular organelles (AVOs). Acridine orange (AO) staining is a widely used method to determine the AVOs. 29, 30 In AO-stained cells, the cytoplasm and nucleolus fluoresce bright green and dim red, whereas acidic compartments fluoresce bright red. 31 To detect and quantify the development of AVOs, leukemia cell lines were treated with or without the different vectors and then performed vital staining with AO as described earlier. 19, 30 Briefly, cultured cells were incubated with AO (Molecular Probes, CA) at 1 mg ml Transmission electron microscope Cells were fixed with 2.5% phosphate-buffered gluteraldehyde, and were then postfixed in 1% phosphatebuffered osmium tetroxide, embedded in Spurr's resin. The ultrathin sections (0.12 mm) were cut, double stained with uranyl acetate and lead citrate. Representative areas were chosen and viewed with a Philips TECNA10 transmission electron microscope.
Immunoprecipitation and western blot analysis
The general procedure immunoblot analysis using antibodies of mda-7/IL-24 (R&D, MN), Beclin-1 (Novus Biologicals, CO), light chain 3 (LC3) (Novus Biologicals), class III PI3K (Abcam, Cambridge, Great Britain), caspase 3 (Cell signaling, MA), and polyadenosine-5-diphosphate-ribose polymerase (PARP; Cell signaling) was as follows. Cells were collected by centrifuging, washing with cold PBS, and resuspending in lysis buffer (20 mM Tris-HCL, pH 7.5, 150 mM NaCL, 1 mM Na2ED-TA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na 3 VO 4 , 1 mg ml -1 leupeptin, and 1 mM PMSF). The cell lysate was centrifuged (20 000 Â g for 30 min at 4 1C), and the supernatant was recovered. Protein concentrations were determined by the Bradford method. 32 Extracted proteins were separated in SDS-polyacrrylamide gels and then transferred onto nitrocellulose membranes (Roche, PA). After blocking 4 h with fat-free milk, the membranes were incubated with the corresponding antibody. Antibody binding was detected by enhanced chemiluminescene using horseradish peroxidase-conjugated secondary antibodies (KPL, MD). Immunoprecipitations were performed as follows. The cells were harvested, washed three times with PBS, and homogenized in RIPA lysis buffer (Santa cruz, CA). The lysate was centrifuged at 10 000 g for 15 min at 4 1C and supernatant was incubated overnight with 1 mg antibodies against Beclin-1 (Epitomics, CA), class III PI3K (Cell signaling), and IgG (Santa cruz), followed by incubation with 20 ml protein A agarose (Santa cruz) at 4 1C. The immune complexes were collected, washed with TBST, boiled for 5 min, and subjected to western blot analysis. 0 -GACAAAAACGUGUCUCGCCTT-3 0 ) using siPORT NeoFX Transfection Agent (Ambion) as described earlier. 33 The transfected cells were used for subsequent experiments 48 h later.
Cellular localization studies
Reverse transcriptase-polymerase chain reaction (RT-PCR) was performed using a PCR kit (Invitrogen) for the detection of Beclin-1 mRNA. The oligonucleotides used in PCR amplification were as follows: sense strand, 5 0 -TCTGGGACAACAAGTTTGAC-3 0 ; antisense strand, 5 0 -CCACTTAAGATTCGTCAGCA-3 0 for Beclin-1; sense strand, 5 0 -GTGGGGCGCCCCAGGCACCA-3 0 ; antisense strand, 5 0 -CCACTTAAGATTCGTCAGCA-3 0 for b-actin. PCR consisted of 30 cycles, with denaturing at 95 1C for 45 s, annealing at 58 1C for 1 min, and extension at 72 1C for 1 min. The reaction was performed in a GeneAmp PCR system 7700 (Perkin Elmer, CT) and PCR products were then subjected to 1.6% polyacrylamide gel electrophoresis.
Establishment of subcutaneous leukemia xenografts and therapy SCID mice (Shanghai Experimental Animal Center of the Chinese Academy of Sciences, Shanghai, China) were housed and maintained in facilities under an instituteapproved animal protocol. For the s.c. xenograft leukemia Mutz-1 mouse model, 3-to 4-week-old female mice were inoculated subcutaneously with 10 Â 10 6 Mutz-1 cells in 0.1 ml volume. When tumor volumes approached 100 mm 3 , the mice were pooled and randomly assigned four groups (eight mice/group): mice receiving PBS as control, mice receiving intratumoral injection of ZD55-IL-24 (2 Â 10 8 pfu), mice receiving intraperitoneal injection of wortmannin (2 mg g -1 ), and mice receiving ZD55-IL-24 combined with wortmannin. Treatments were administered each day for 5 days. The tumor volume was calculated as 4p/3 Â (tumor width/2) 2 Â (tumor length/2). 34 
Statistical analysis
All data were presented as means±s.e. Data were analyzed using the Student's t-test and the one-way analysis of variance (ANOVA) for statistical significance. P-values were considered significant in o0.05.
Results
Constitutive and enforced expression of mda-7/IL-24 in leukemia cells
We first examined the expression of mda-7/IL-24 proteins in lysates from a number of leukemia cell lines, as well as primary leukemia blasts from 10 patients with AML. The expression of mda-7/IL-24 was detected in the most of examined cell lines, especially in NB4, THP, Mutz-1, and K562 ( Figure 1a) . It was also detected in all tested primary leukemia cells, albeit with varying degrees (Figure 1b) . However, the protein expression of mda-7/ IL-24 was lower in normal PBMNCs than in AML primary cells (P ¼ 0.0096; Figure 1c ). These findings suggest that mda-7/IL-24 is constitutively expressed in leukemia cells. To investigate the effects of overexpression of mda-7/IL-24 in leukemia cells, Mutz-1, L428, and K562 cells were infected with ZD55-IL-24 (MOIs of 50 and 100), a CRAd representing a viable vector for enforced expression of mda-7/IL-24. 26, 35 The infection efficiency and time of this vector for leukemia cells was determined by ZD55 carrying enhanced green fluorescence protein genes (ZD55-EGFP; data not shown). As shown in Figure 1d , Mutz-1 cells infected with ZD55-IL-24 for 72 h expressed much higher mda-7/IL-24 protein compared with the PBS-treated or mock vector-treated Inhibiting autophagy and mda-7/IL-24 in leukemia C Yang et al controls in a dose-dependent manner, which was also observed in ZD55-IL-24-treated K562 and L428 cells (data not shown).
Overexpression of mda-7/IL-24 induces autophagy in leukemia cells
As autophagy is characterized by the development of AVOs, 29, 31 we examined the appearance of AVOs in ZD55-IL-24-infected leukemia cells using AO staining. AO is a lysosomotropic agent, the protonated form of which accumulates in acidic compartments and forms bright red fluorescent aggregates. 36 As shown in Figure 2A , obvious AO staining of AVOs was observed in Mutz-1 cells treated with ZD55-IL-24, but not in PBS-, or empty vector-treated controls. A similar but weak effect was also observed in the cells after infection with replication-defective adenovector Ad-IL-24. The formation of AVOs was also detected in K562 and L428 cells treated by ZD55-IL-24 (data not shown). In agreement with these results, electron microscopy revealed a few autophagic vesicles in Mutz-1 cells infected with Ad-IL-24, and many autophagic vacuoles including aggregated vacuoles, lamellar structures, and vacuoles with residual digested material in the cells treated with ZD55-IL-24. In contrast, these vacuoles were not seen in the control cells ( Figure 2B ). To further highlight formation of autophagosomes, we checked the cells by immunoblotting analysis using antibodies against microtubule-associated protein 1 LC3, a specific marker of mammalian autophagy. 28 The conversion of LC3-I (18 kDa) to LC3-II (16 kDa) was found in the ZD55-IL-24-treated cells ( Figure 2C ). Next, we stably expressed GFP-LC3 in leukemia cells and analyzed GFP-LC3-expressing cells before and after ZD55-IL-24 treatment. Treatment of ZD55-IL-24 resulted in an increased punctuate staining of GFP-LC3 in leukemia cells ( Figure 2D ). Overall, these findings led us to conclude that mda-7/IL-24 has a stimulatory effect on autophagy. Inhibiting autophagy and mda-7/IL-24 in leukemia C Yang et al Upregulation of Beclin-1 is required for mda-7/IL-24-induced autophagy Earlier, we showed that robust accumulation of autophagy protein Beclin-1 was involved in the autophagy of leukemia cells in response to arsenic trioxide. 27 Thus, we performed western blot analysis to examine the protein expression of Beclin-1. Results showed significant increases in Beclin-1 protein expression in the Mutz-1, L428, and K562 cell lines infected with ZD55-IL-24 at MOIs of 50 and 100 for 72 h, but not in the cells treated with an empty vector (data not shown) and PBS control ( Figure 3A) . Furthermore, upregulation of Beclin-1 mRNA was confirmed in Mutz-1 cells after 48 h of ZD55-IL-24 treatment ( Figure 3B ). To determine whether the upregulation of Beclin-1 is required for ZD55-IL-24-induced autophagy, we used siRNA to knockdown Beclin-1 in Mutz-1 cells. Beclin-1 siRNA resulted in a considerable decrease in ZD55-IL-24-induced formation of AVOs ( Figure 3C ). Beclin-1 western blots indicated effective knockdown of Beclin-1 protein expression during ZD55-IL-24 treatment that was added 48 h after siRNA transfection ( Figure 3D ).
As localization of mda-7/IL-24 in the endoplasmic reticulum (ER) in both normal and cancer cells and colocalization of Beclin-1 with intracytoplasmic structures including mitochondria, ER, and perinuclear membrane were observed earlier, [37] [38] [39] it is possible that interactions between mda-7/IL-24 and Beclin-1 in the ER of cancer cells exist. We examined the subcellular colocalization of mda-7/IL-24 with Beclin-1 in Mutz-1 cells after infection of ZD55-IL-24. Coexpression of mda-7/IL-24 with Beclin-1 was observed in the extranuclear regions of individual cell (Figure 4a ). Western blot analysis using anti-mda-7/IL-24 antibodies showed that mda-7/IL-24 was detected in the immunocomplexes precipitated by an anti-Beclin-1 antibody (Figure 4b ). These results suggest that mda-7/IL-24 may associate with Beclin-1 in leukemia cells.
Inhibition of autophagy by PI3K inhibitor wortmannin promotes apoptosis
Beclin-1/class III PI3K regulates cell growth and controls autophagy as a complex. 40, 41 We therefore assessed subcellular localization of Beclin-1 and class III PI3K. Using confocal microscopy, we noted cytoplasmic colocalization of Beclin-1 and class III PI3K ( Figure 5A ). We then examined the interaction between these two proteins. As shown in Figure 5B , anti-class III PI3K antibody did not coprecipitate Beclin-1 protein in the PBS-treated cells; however, in ZD55-IL-24-treated cells, Beclin-1 was detected after immunoprecipitation. The negative control antibody (IgG) did not immunoprecipitate Beclin-1 protein. We next performed the reciprocal experiment with PBS-and ZD55-IL-24-treated cell lysates immunoprecipitated by an antibody against Beclin-1. Class III PI3K protein was detected only in ZD55-IL-24-treated lysates ( Figure 5B ). Together, these data confirm the protein-protein interaction and suggest Beclin-1/class III Further, to confirm the involvement of PI3K pathway in mda-7/IL-24-induced autophagy, we used wortmannin, a specific inhibitor of PI3K, to assess whether this agent could suppress mda-7/IL-24-induced autophagy. The autophagic vacuole formation was measured by using the fluorescent dye MDC, which can specifically stain autophagosomes. 42 Microscopic analysis showed that mda-7/IL-24-treatment induced an increased dot-like pattern of MDC staining in the cytoplasm of Mutz-1 ( Figure 5C ) and K562 cells (data not shown), which was significantly suppressed after wortmannin treatment. Activation of Beclin-1 and class III PI3K was markedly inhibited, and the conversion from LC3-I to LC3-II was also suppressed after wortmannin administration ( Figure 5D ). Furthermore, our results showed that wortmannin, which resulted in a considerable decrease in mda-7/IL-24-induced autophagy, promoted the cleavage of caspase 3 and PARP ( Figure 5D ). We next examined the effects of inhibition of autophagy on cell growth and viability by MTT assay. The antileukemia 
Inhibition of autophagy strongly potentiates the antileukemia activity of ZD55-IL-24 in vivo
We established human leukemia xenografts in 3-4 weeks female SCID mice by inoculating them with Mutz-1 cells. As we had observed earlier, 35 treatment of Mutz-1 tumors with ZD55-IL-24 led to significant tumor suppression when compared with control vectors (data not shown) or PBS treatment ( Figure 6 ). After 5 days of treatment, one mouse of each group was sacrificed, and tumors were dissected. Whole-tumor-cell lysates from PBS control and ZD55-IL-24-treated mice were subjected to western blotting to assess in vivo protein expression of mda-7/ IL-24 and Beclin-1, as well as the conversion from the LC3-I isoform to the LC3-II isoform. As shown in Figure 6b , the tumor tissue from ZD55-IL-24-treated mouse showed significant increased expression of mda-7/ IL-24 and Beclin-1 as compared with the tumor tissue from control animal. The conversion of LC3-I to LC3-II existed in the tumor cells treated with ZD55-IL-24, suggesting autophagy of cancer cells in vivo.
To determine whether the inhibition of autophagy could enhance the antitumor activity of ZD55-IL-24 in vivo, mice carrying established Mutz-1 xenografts were treated with ZD55-IL-24 alone or in combination with a PI3K inhibitor. We used wortmannin as PI3K inhibitor in vivo, as it is more soluble and is currently in preclinical trails. 43 From study day 14 onwards, the mean tumor volume of mice treated with ZD55-IL-24 combined with wortmannin remained close to the starting volume. In contrast, the tumor volumes of mice treated with ZD55-IL-24, wortmannin, and PBS control increased rapidly, and the mean tumor volumes increased to 513, 544, and 870% of starting tumor volumes, respectively (Figure 6c ). Over the course of the experiment, the control tumors grew approximately 31-fold, whereas the wortmanninand ZD55-IL-24-treated tumors grew approximately 22-and 16-fold, respectively (wortmannin vs control, P ¼ 0.599; ZD55-IL-24 vs control, P ¼ 0.0065, t-test). Interestingly, treatment of ZD55-IL-24 combined with wortmannin significantly reduced tumor growth with an approximately nine-fold size reduction compared with PBS-treated tumors (combination vs wortmannin, Po0.0001; combination vs ZD55-IL-24, Po0.0001, t-test). These results for the first time show that inhibition of autophagy induced by overexpression of mda-7/IL-24 leads to significantly improved antileukemia efficacy in vivo.
Discussion
Mda-7/IL-24 is a novel tumor suppressor gene that has a broad range of antitumor properties including an ability to selectively induce apoptosis in tumor cells, promote 'bystander' antitumor effects, inhibit tumor angiogenesis, and modulate immune response. 44 However, the effects of mda-7/IL-24 on hematopoietic malignances are unclear. An inconsistent effect was reported in chronic lymphocytic leukemia (CLL) B-cells in which mda-7/IL-24 promoted the survival of these cancer cells via increasing phosphorylation of p38 mitogen-activated protein kinase. 45 The overexpression of mda-7/IL-24 mRNA and protein was observed in all tested CLL B-cells, but not in normal B-cells. Earlier studies showed that mda-7/IL-24 is restricted expression in specific normal tissues, including thymus, spleen, and peripheral blood leukocytes, and in certain cell types. 46 Therefore, it is worthwhile to investigate the effects of overexpression of mda-7/IL-24 on leukemic cells. In this study, we examined the presence of mda-7/IL-24 protein in lysates from a panel of leukemia cell lines and blasts of AML patient, and confirmed that mda-7/IL-24 was detectable with variable intensity in the most of tested cell lines and AML samples. Using a CRAd ZD55-IL-24, we showed that enforced expression of mda-7/IL-24 in leukemic cells resulted in obvious induction of vacuolization and double-membrane structures. These were detected by conventional electron microscopy. Besides, the formation of AVOs and lapidated LC3-II was elicited by the enforced expression of mda-7/IL-24, suggesting the induction of autophagy in leukemia cells. A recent report suggests that GST-mda-7 fusion protein induces autophagy in human glioma cells, in which inhibition of autophagy by knockdown of ATG5 and Beclin-1 expression or overexpression of HSP70 reduces cytotoxicity of GST-mda-7 fusion protein against glioma cells; 47 however, the role of mda-7/IL-24-induced autopgay in leukemia cell death or survival is unclear. Inhibiting autophagy and mda-7/IL-24 in leukemia C Yang et al Although growing amount of evidence points to an inverse relationship between autophagy and malignant growth, 23, 48 the role of autophagy during tumor progression is probably more complex, because autophagic vacuoles have been shown in several types of human tumor samples including ganglioneuroma, infiltrating ductal carcinoma of the breast, adenocarcinoma of the lung, and pancreatic adenocarcinoma. 49 Recently, autophagy has been shown to be one of the defense mechanisms offered by cancer cells in response to nutrient deprivation, 50 radiation, 31, 51 or chemotherapeutic agent like temozolomide. 52 In addition, it was reported that camptothecin activated an apoptotic pathway, simultaneously triggering an autophagic response in breast cancer cells that delayed their apoptotic death. 53 On the basis of the observation that mda-7/IL-24 promoted the Inhibiting autophagy and mda-7/IL-24 in leukemia C Yang et al survival of CLL B-cells together with induction of autophagy by the overexpression of mda-7/IL-24 shown in this study, we hypothesized that autophagy induced by mda-7/IL-24 could provide a protection for leukemia cells against apoptosis. As expected, we found that inhibition of mda-7/IL-24-induced autophagy by a pharmacological inhibitor of PI3K, wortmannin or LY294002, enhanced cell death in leukemia in vitro. Our finding supports the earlier reports, in which augmented anticancer activity was achieved in leukemia cells and lymphoma cells by disrupting autophagy. 21, 54 Importantly, we observed a minimal cytotoxicity against tumors on treatment with wortmannin alone in animal experiments. Treatment with ZD55-IL-24 alone showed a modest antitumor activity. In contrast, the combination of wortmannin with ZD55-IL-24 resulted in a significant suppression of tumor growth in vivo, suggesting that targeting autophagy pathway is a promising therapeutic strategy to enhance mda-7/IL-24-induced cell death in leukemia.
It is shown that autophagy can be pharmacologically inhibited by class III PI3K inhibitors including wortmannin or by inhibitors of the lysosomal proton pump such as bafilomycin A1 and lysosomotropic alkalines such as chloroquine, which prevent the fusion of autophagosomes and lysosomes. 21, 23, 54 All of these pharmacological agents are nonspecific for the autophagy pathway and even toxic, although some of them are clinically available and may be helpful for treating diseases associated with autophagy deregulation. Therefore, new agents targeting autophagy pathway are needed for the clinical application.
Autophagy is a multistep process controlled by sensor and effector molecules. Effectors are divided into type-I and type-II. 55 The activity of type-I effectors, which lead to the formation of autophagosomes, is regulated by the formation of a class III PI3K/Beclin-1 complex. 40, 41 Type-II effectors such as Lamp-2 and Rab are involved in the maturation of autophagosomes. 55 Here, we provide evidence of an upregulation of Beclin-1 induced by overexpression of mda-7/IL-24 in leukemia cells, consistent with an earlier study showing increased Beclin-1 expression in glioma cells after treatment with mda-7/IL-24. 47 This work also shows the cytoplasmic colocalization of Beclin-1 and class III PI3K in the cells with enhanced expression of mda-7/IL-24. Furthermore, autophagy could be suppressed by the PI3K inhibitor, wortmannin, or by the specific siRNA against Beclin-1, suggesting that autophagy triggered by mda-7/IL-24 is mediated by the type-I effectors.
Beclin-1, the mammalian ortholog of yeast Atg6, is part of a multiprotein complex, and acts as a platform which recruits activators or repressors of Beclin-1/class III PI3K-dependent autophagy, having an important function during the formation of the autophagosome. 23, 56 The upregulation of Beclin-1 has been shown to be essential in inducing autophagy by chemotherapeutic agent, 16 radiation, 57 and mda-7/IL-24. 47 But, how mda-7/IL-24 modulates Beclin-1 expression and triggers autophagic process is unclear. In this study, we showed that majority of Beclin-1 and mda-7/IL-24 colocalized to the cytoplasmic of leukemia cells, and mda-7/IL-24 was coimmunoprecipitated with Beclin-1. These data suggest that a interaction between these two proteins exists; however, further studies are needed to provide direct evidences of interaction between mda-7/IL-24 and Beclin-1, and to investigate the mechanisms by which mda-7/IL-24 regulate the expression of Beclin-1.
In conclusion, the results of ours experiments show for the first time that inhibition of autophagy induced by mda-7/IL-24 strongly potentiate the antileukemia activity in vitro and in vivo. These findings are consistent with the concept that inhibition of autophagy, rather than stimulation of autophagy, may be beneficial in cancer treatment, and suggest that inhibiting the autophagy triggered by anticancer therapies is a promising strategy to strongly augment their antitumor activity.
